• Accueil
• tpex
• Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised

4.9 (159) · € 27.99 · En Stock

PDF] Cisplatin and fluorouracil with or without panitumumab in

Head and Neck Tumors in Older Adults: Systemic Treatments and

Systemic Treatment Sequencing and Prediction of First-line Therapy

PDF) Induction Docetaxel, Cisplatin, and Cetuximab Followed by

A pilot study of camrelizumab with docetaxel and cisplatin for the

Cancers, Free Full-Text

Durvalumab with or without tremelimumab versus the EXTREME regimen

Full article: Cost-effectiveness of pembrolizumab for the first

Frontiers Multimodality treatment in recurrent/metastatic

PDF] Pembrolizumab alone or with chemotherapy versus cetuximab

GEDEFO on X: Docetaxel can be substituted for 5-FU in combination

Frontiers Weekly Paclitaxel, Carboplatin, and Cetuximab as First

Biomedicines, Free Full-Text